Perioperative Anticoagulant Use (Dabigatran, Rivaroxaban, or Apixaban) for Elective Surgery/Procedure Evaluation in Patients With Atrial Fibrillation (AF).

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
Indications Arterial thrombosis; Thromboembolism
Focus Adverse reactions
Acronyms PAUSE

05 Aug 2019 Results (n=3007) assessing the safety of a standaedized perioperative DOAC management strategy published in the JAMA Internal Medicine
05 Aug 2019 According to a The Feinstein Institute for Medical Research media release, Professor Alex C. Spyropoulos, MD, was co-principal investigator for the study.
05 Aug 2019 According to a The Feinstein Institute for Medical Research media release, results from this study were published in thelatest issue of JAMA Internal Medicine.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com